Phase I clinical evaluation of <sup>99m</sup>Tc-labeled Affibody molecule for imaging HER2 expression in breast cancer
Olga Bragina, В. И. Чернов, Мария Сергеевна Ларькина, Anstasiya Rybina, Roman Zelchan, Е. Yu. Garbukov, Maryam Oroujeni, Annika Loftenius, Anna Orlova, Jens Benn Sørensen, Fredrik Y. Frejd, Vladimir Tolmachev
Abstract
Tc-ZHER2:41071 appear safe and exhibit favorable dosimetry. The protein dose of 1000 µg provides the best discrimination between HER2-positive and HER2-low/negative expression of HER2 according to the definition used for current HER2-targeting drugs.
Topics & Concepts
BiodistributionMolecular imagingMedicineNuclear medicinePositron emission tomographyBreast cancerImaging agentIn vivoCancerPathologyInternal medicineBiologyBiotechnologyMonoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer ResearchRadiopharmaceutical Chemistry and Applications